Psilocybin rTMS for Treatment Resistant Depression
RecruitingNCT06132178Phase: PHASE2Started 2025-01-10
Summary
The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, o
Eligibility
Sex
ALL
Min Age
22 Years
Max Age
65 Years
Locations
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Austin, Texas, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT06132178